Ra Medical Systems Announce Issuance of Additional International Patent

Rhea-AI Summary

Ra Medical Systems (RMED:NYSE/American) announced that its subsidiary, Catheter Precision, has received a new international patent for its VIVO technology in Japan. The patent, titled Methods of Cardiac Mapping and Model Merging, adds to the company's growing patent portfolio, now exceeding fifty patents and applications. Executive Chairman, David Jenkins, emphasized the importance of intellectual property in enhancing market presence and value. The VIVO™ system, a non-invasive 3D imaging solution, assists in identifying the origins of ventricular arrhythmias, improving workflow and reducing procedure times.

Positive

• Issuance of a new international patent for VIVO technology enhances intellectual property portfolio.
• VIVO technology has FDA marketing clearance and CE mark, validating its market readiness.
• Patent adds to existing portfolio of over fifty patents, strengthening market position.

Negative

• None.

FORT MILL, SC / ACCESSWIRE / March 17, 2023 / Ra Medical Systems, Inc. (RMED:NYSE/American) today announced that its wholly owned subsidiary, Catheter Precision, Inc., has received notification of an additional issuance of a new international patent. The patent is part of the evolving number of patents surrounding the company's VIVO technology. The patent, entitled "Methods of Cardiac Mapping and Model Merging" has been issued in the country of Japan.

RMED's Executive Chairman, David Jenkins, commented. "As a medical device company, we realize that intellectual property is a key part of growing not only our value but also our market presence. We are pleased that our technology in the field of cardiac electrophysiology continues to be recognized as unique and different. This patent combines with our entire estate of over fifty patents and patent applications covering our different product areas."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.

View source version on accesswire.com:
https://www.accesswire.com/744254/Ra-Medical-Systems-Announce-Issuance-of-Additional-International-Patent

FAQ

What is the latest patent announcement from Ra Medical Systems (RMED)?

Ra Medical Systems announced a new international patent for its VIVO technology in Japan.

How does the VIVO technology impact cardiac arrhythmia treatment?

VIVO is a non-invasive 3D imaging system that helps identify the source of ventricular arrhythmias, improving workflow and reducing procedure times.

How many patents does Ra Medical Systems currently hold?

Ra Medical Systems has over fifty patents and patent applications related to its various product areas.

What is the significance of the new patent for RMED?

The new patent strengthens RMED's intellectual property portfolio, which is crucial for its market presence and growth.